The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Short-acting B2 Agonists Market Research Report 2024
Synopsis
Short-acting B2 agonists (SABAs) are albuterol, levalbuterol, metaproterenol, and terbutaline, and they are prescribed for bronchospasm caused by COPD, bronchial asthma, or emphysema.
Global Short-acting B2 Agonists market is projected to reach US$ 5919 million in 2029, increasing from US$ 4791 million in 2022, with the CAGR of 4.1% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Short-acting B2 Agonists market research.
The inhalation combination product market is driven by the increasing prevalence of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) and the demand for more effective and convenient treatment options. Inhalation combination products offer a combination of two or more medications in a single device, providing patients with better disease management and improved treatment adherence. These products offer advantages such as simplified dosing regimens, enhanced efficacy, and reduced side effects compared to multiple separate inhalers. Additionally, advancements in inhalation technology, such as metered-dose inhalers and dry powder inhalers, have further fueled the adoption of combination products. However, the market also faces challenges, including the complexity of formulation development and the need for rigorous testing to ensure compatibility and stability of the combined medications. Moreover, regulatory requirements for combination products can be more stringent than individual drugs, making the approval process more challenging. To succeed in this market, manufacturers must invest in research and development to optimize combination therapies, address regulatory concerns, and educate healthcare professionals and patients about the benefits of inhalation combination products.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Short-acting B2 Agonists market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Bayer AG
Teva
Roche
Viatris
GSK
Cipla Limited
Johnson & Johnson
Merck
Segment by Type
Albuterol
Metaproterenol
Levalbuterol
Other
Segment by Application
COPD
Asthma
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Short-acting B2 Agonists report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Short-acting B2 agonists (SABAs) are albuterol, levalbuterol, metaproterenol, and terbutaline, and they are prescribed for bronchospasm caused by COPD, bronchial asthma, or emphysema.
Global Short-acting B2 Agonists market is projected to reach US$ 5919 million in 2029, increasing from US$ 4791 million in 2022, with the CAGR of 4.1% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Short-acting B2 Agonists market research.
The inhalation combination product market is driven by the increasing prevalence of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) and the demand for more effective and convenient treatment options. Inhalation combination products offer a combination of two or more medications in a single device, providing patients with better disease management and improved treatment adherence. These products offer advantages such as simplified dosing regimens, enhanced efficacy, and reduced side effects compared to multiple separate inhalers. Additionally, advancements in inhalation technology, such as metered-dose inhalers and dry powder inhalers, have further fueled the adoption of combination products. However, the market also faces challenges, including the complexity of formulation development and the need for rigorous testing to ensure compatibility and stability of the combined medications. Moreover, regulatory requirements for combination products can be more stringent than individual drugs, making the approval process more challenging. To succeed in this market, manufacturers must invest in research and development to optimize combination therapies, address regulatory concerns, and educate healthcare professionals and patients about the benefits of inhalation combination products.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Short-acting B2 Agonists market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Bayer AG
Teva
Roche
Viatris
GSK
Cipla Limited
Johnson & Johnson
Merck
Segment by Type
Albuterol
Metaproterenol
Levalbuterol
Other
Segment by Application
COPD
Asthma
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Short-acting B2 Agonists report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 Short-acting B2 Agonists Market Overview
1.1 Product Overview and Scope of Short-acting B2 Agonists
1.2 Short-acting B2 Agonists Segment by Type
1.2.1 Global Short-acting B2 Agonists Market Value Comparison by Type (2023-2029)
1.2.2 Albuterol
1.2.3 Metaproterenol
1.2.4 Levalbuterol
1.2.5 Other
1.3 Short-acting B2 Agonists Segment by Application
1.3.1 Global Short-acting B2 Agonists Market Value by Application: (2023-2029)
1.3.2 COPD
1.3.3 Asthma
1.3.4 Other
1.4 Global Short-acting B2 Agonists Market Size Estimates and Forecasts
1.4.1 Global Short-acting B2 Agonists Revenue 2018-2029
1.4.2 Global Short-acting B2 Agonists Sales 2018-2029
1.4.3 Global Short-acting B2 Agonists Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Short-acting B2 Agonists Market Competition by Manufacturers
2.1 Global Short-acting B2 Agonists Sales Market Share by Manufacturers (2018-2023)
2.2 Global Short-acting B2 Agonists Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Short-acting B2 Agonists Average Price by Manufacturers (2018-2023)
2.4 Global Short-acting B2 Agonists Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Short-acting B2 Agonists, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Short-acting B2 Agonists, Product Type & Application
2.7 Short-acting B2 Agonists Market Competitive Situation and Trends
2.7.1 Short-acting B2 Agonists Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Short-acting B2 Agonists Players Market Share by Revenue
2.7.3 Global Short-acting B2 Agonists Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Short-acting B2 Agonists Retrospective Market Scenario by Region
3.1 Global Short-acting B2 Agonists Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Short-acting B2 Agonists Global Short-acting B2 Agonists Sales by Region: 2018-2029
3.2.1 Global Short-acting B2 Agonists Sales by Region: 2018-2023
3.2.2 Global Short-acting B2 Agonists Sales by Region: 2024-2029
3.3 Global Short-acting B2 Agonists Global Short-acting B2 Agonists Revenue by Region: 2018-2029
3.3.1 Global Short-acting B2 Agonists Revenue by Region: 2018-2023
3.3.2 Global Short-acting B2 Agonists Revenue by Region: 2024-2029
3.4 North America Short-acting B2 Agonists Market Facts & Figures by Country
3.4.1 North America Short-acting B2 Agonists Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Short-acting B2 Agonists Sales by Country (2018-2029)
3.4.3 North America Short-acting B2 Agonists Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Short-acting B2 Agonists Market Facts & Figures by Country
3.5.1 Europe Short-acting B2 Agonists Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Short-acting B2 Agonists Sales by Country (2018-2029)
3.5.3 Europe Short-acting B2 Agonists Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Short-acting B2 Agonists Market Facts & Figures by Country
3.6.1 Asia Pacific Short-acting B2 Agonists Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Short-acting B2 Agonists Sales by Country (2018-2029)
3.6.3 Asia Pacific Short-acting B2 Agonists Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Short-acting B2 Agonists Market Facts & Figures by Country
3.7.1 Latin America Short-acting B2 Agonists Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Short-acting B2 Agonists Sales by Country (2018-2029)
3.7.3 Latin America Short-acting B2 Agonists Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Short-acting B2 Agonists Market Facts & Figures by Country
3.8.1 Middle East and Africa Short-acting B2 Agonists Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Short-acting B2 Agonists Sales by Country (2018-2029)
3.8.3 Middle East and Africa Short-acting B2 Agonists Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Short-acting B2 Agonists Sales by Type (2018-2029)
4.1.1 Global Short-acting B2 Agonists Sales by Type (2018-2023)
4.1.2 Global Short-acting B2 Agonists Sales by Type (2024-2029)
4.1.3 Global Short-acting B2 Agonists Sales Market Share by Type (2018-2029)
4.2 Global Short-acting B2 Agonists Revenue by Type (2018-2029)
4.2.1 Global Short-acting B2 Agonists Revenue by Type (2018-2023)
4.2.2 Global Short-acting B2 Agonists Revenue by Type (2024-2029)
4.2.3 Global Short-acting B2 Agonists Revenue Market Share by Type (2018-2029)
4.3 Global Short-acting B2 Agonists Price by Type (2018-2029)
5 Segment by Application
5.1 Global Short-acting B2 Agonists Sales by Application (2018-2029)
5.1.1 Global Short-acting B2 Agonists Sales by Application (2018-2023)
5.1.2 Global Short-acting B2 Agonists Sales by Application (2024-2029)
5.1.3 Global Short-acting B2 Agonists Sales Market Share by Application (2018-2029)
5.2 Global Short-acting B2 Agonists Revenue by Application (2018-2029)
5.2.1 Global Short-acting B2 Agonists Revenue by Application (2018-2023)
5.2.2 Global Short-acting B2 Agonists Revenue by Application (2024-2029)
5.2.3 Global Short-acting B2 Agonists Revenue Market Share by Application (2018-2029)
5.3 Global Short-acting B2 Agonists Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Bayer AG
6.1.1 Bayer AG Corporation Information
6.1.2 Bayer AG Description and Business Overview
6.1.3 Bayer AG Short-acting B2 Agonists Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Bayer AG Short-acting B2 Agonists Product Portfolio
6.1.5 Bayer AG Recent Developments/Updates
6.2 Teva
6.2.1 Teva Corporation Information
6.2.2 Teva Description and Business Overview
6.2.3 Teva Short-acting B2 Agonists Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Teva Short-acting B2 Agonists Product Portfolio
6.2.5 Teva Recent Developments/Updates
6.3 Roche
6.3.1 Roche Corporation Information
6.3.2 Roche Description and Business Overview
6.3.3 Roche Short-acting B2 Agonists Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Roche Short-acting B2 Agonists Product Portfolio
6.3.5 Roche Recent Developments/Updates
6.4 Viatris
6.4.1 Viatris Corporation Information
6.4.2 Viatris Description and Business Overview
6.4.3 Viatris Short-acting B2 Agonists Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Viatris Short-acting B2 Agonists Product Portfolio
6.4.5 Viatris Recent Developments/Updates
6.5 GSK
6.5.1 GSK Corporation Information
6.5.2 GSK Description and Business Overview
6.5.3 GSK Short-acting B2 Agonists Sales, Revenue and Gross Margin (2018-2023)
6.5.4 GSK Short-acting B2 Agonists Product Portfolio
6.5.5 GSK Recent Developments/Updates
6.6 Cipla Limited
6.6.1 Cipla Limited Corporation Information
6.6.2 Cipla Limited Description and Business Overview
6.6.3 Cipla Limited Short-acting B2 Agonists Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Cipla Limited Short-acting B2 Agonists Product Portfolio
6.6.5 Cipla Limited Recent Developments/Updates
6.7 Johnson & Johnson
6.6.1 Johnson & Johnson Corporation Information
6.6.2 Johnson & Johnson Description and Business Overview
6.6.3 Johnson & Johnson Short-acting B2 Agonists Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Johnson & Johnson Short-acting B2 Agonists Product Portfolio
6.7.5 Johnson & Johnson Recent Developments/Updates
6.8 Merck
6.8.1 Merck Corporation Information
6.8.2 Merck Description and Business Overview
6.8.3 Merck Short-acting B2 Agonists Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Merck Short-acting B2 Agonists Product Portfolio
6.8.5 Merck Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Short-acting B2 Agonists Industry Chain Analysis
7.2 Short-acting B2 Agonists Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Short-acting B2 Agonists Production Mode & Process
7.4 Short-acting B2 Agonists Sales and Marketing
7.4.1 Short-acting B2 Agonists Sales Channels
7.4.2 Short-acting B2 Agonists Distributors
7.5 Short-acting B2 Agonists Customers
8 Short-acting B2 Agonists Market Dynamics
8.1 Short-acting B2 Agonists Industry Trends
8.2 Short-acting B2 Agonists Market Drivers
8.3 Short-acting B2 Agonists Market Challenges
8.4 Short-acting B2 Agonists Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
